SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors monitor its lead clinical candidate, AVTX-009, with the community actively discussing potential Phase 2 trial readouts and bullish analyst coverage that underscores its long-term upside. Market participants are closely watching the high trading volume and volatility, while simultaneously expressing caution over the companys ongoing capital requirements and historical dependence on successful clinical data.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive is generating buzz following its collaboration with Synthetix to build derivatives on Ethereum, fueling optimism among holders regarding potential protocol growth. Community members are actively tracking the token's technical strength and buyback mechanisms as the asset displays steady upward momentum.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Petroleo Brasileiro (PBR) is trending as investors weigh strong production milestones and offshore expansion plans against ongoing concerns regarding political interference and fluctuating oil price environments. The community remains focused on the stock's potential for significant dividend payouts and its status as a value play, while closely monitoring geopolitical risks and regulatory hurdles affecting its deepwater drilling prospects.

FLOKI is a community-driven, multi-chain utility token that powers a broad ecosystem including decentralized gaming, finance, and educational platforms. Originally evolving from a meme-based asset, the project now focuses on a utility-driven model centered around three pillars: community engagement, technical utility, and global charity work, balancing this ecosystem growth with social impact, such as building schools in developing nations like Ghana and Nigeria.  Key features include Valhalla, an NFT metaverse game where the token serves as the primary currency for capturing creatures and upgrading characters. The ecosystem also features the FlokiFi Locker for securing digital assets and the University of FLOKI for web3 education,with real-world integration facilitated through a prepaid debit card for everyday purchases at global stores. Staking FLOKI allows users to earn rewards in a sister token.  The project is led by a group of core advisors known by pseudonyms such as Sabre and B (The Viking) and is officially backed by DWF Labs, a major digital asset investment firm and market maker. While a small tax on decentralized trades helps fund development, value moves through the system as users utilize the token to pay for in-game items, access asset-locking services, or purchase merchandise.

Floki Token

$FLOKI is seeing increased activity as the community celebrates the launch of its ETP in Europe, which is being viewed as a significant milestone for institutional accessibility. Traders are currently split between long-term optimism about the token's ecosystem developmentssuch as gaming and DeFi toolsand frustration over recent price volatility that has left many questioning the current market trend.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending after securing a major 10-year, $865 million colocation agreement with Nscale for its NC-1 AI data center, a development the community sees as a long-awaited catalyst to validate the company's business model. Investors are actively discussing the stock's low float, potential for a short squeeze, and the implications of this contract on the company's long-term revenue growth and ability to attract future hyperscale clients.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is currently a major focus for traders as the stock attempts a recovery following a multi-year downtrend, with community sentiment split between those viewing it as a deep-value turnaround play and others concerned about long-term margin pressure from labor costs and losing Amazon volume. Investors are actively monitoring the stock's consolidation around the $100 level, looking for signs that restructuring efforts and cost-cutting can successfully defend the dividend and drive a sustained breakout.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival Corp (CCL) is currently experiencing intense volatility as investors weigh resilient consumer travel demand against broader macroeconomic pressures, specifically rising fuel costs and geopolitical tensions in the Middle East. While the community is actively debating whether the recent share price decline represents an oversold buying opportunity ahead of upcoming earnings, others are closely monitoring fuel surcharges and potential margin impacts.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a major management shake-up where long-time CEO Peter Greenleaf was replaced by board chair Kevin Tang, a move that investors view as a pivotal step toward unlocking shareholder value and accelerating potential acquisition efforts. The community is actively discussing the leadership transition, Tang's significant investment with no compensation, and the expectation that the new team will prioritize a strategic sale or partnership.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is seeing heightened volatility as investors weigh the impact of shifting rate expectations and rotation out of speculative growth assets. Community discussion is sharply divided between those tracking Cathie Wood's tactical shifts in and out of crypto-linked stocks and critics focusing on the fund's long-term performance struggles.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is currently the subject of intense community debate regarding the likelihood of an FDA approval for its skin cancer treatment, RP1, ahead of its upcoming PDUFA date. Investors are polarized between those anticipating a positive regulatory outcome due to management's recent BLA resubmission and those betting on a second complete response letter (CRL) based on historical study design concerns and persistent regulatory uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CPRX or UTHR: Which Is the Better Value Stock Right Now?

CPRX vs. UTHR: Which Stock Is the Better Value Option?

OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study

Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3. 

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.

AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD

Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.

NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up

Novo Nordisk stock jumps after launching a Wegovy subscription plan to cut costs, expand telehealth access and improve treatment adherence for sustained obesity care.

Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio

BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Evaluating Acadia Healthcare's Outlook: Hold for Now or Fold?

ACHC rides on strong demand and expansion gains, but premium valuation, rising costs, and weak efficiency raise caution for investors weighing next moves.

Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND

RARE's IND for UX016, a novel sialic acid prodrug targeting GNEM, a rare muscle disease, gets accepted by the FDA. The first-in-human study is slated for H2'26.

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Catalyst Pharmaceuticals Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

CPRX
Catalyst Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CPRX News

CPRXCatalyst Pharmaceuticals Inc